Inhibitory effect of azelastine hydrochloride on synthesis and release of platelet activating factor from human alveolar macrophages

Shindo, Kazutoshi; Machida, Makiyo; Hirai, Yoshihiro; Fukumura, Motonori

doi:10.1016/s0952-3278(97)90561-5

Cited by 5 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Macrophages are the predominant cell type within the lung alveoli (Shindo et al 1997) and also represent a major source of inflammatory mediators implicated in the pathophysiology of asthma (Menard and Bissonnette 2000). In addition, platelet activating factor (PAF) is a potent lipid mediator, associated with key features of asthma such as airway constriction, eosinophil infiltration, edema, and mucus accumulation (Henig et al …”

Section: Azelastinementioning

confidence: 99%

“…An in vitro study has shown that azelastine inhibits PAF-induced bronchoconstriction in anesthetized guinea pigs (Achterrath-Tuckermann et al 1988). The inhibitory effects of azelastine hydrochloride on PAF-like activity were investigated in vitro in eosinophils (Shindo and Fukumura 1996) and macrophages (Shindo et al 1997) obtained from 15 asthmatics. Eosinophils were also obtained from 20 nonasthmatics, while macrophages were obtained from 15 nonasthmatic subjects for comparison purposes.…”

Section: )mentioning

confidence: 99%

See 1 more Smart Citation

Application of Kinetic and Dynamic Data for Antihistamines to Risk Characterization in Sensitive Populations

Skowronski

Abdel‐Rahman

Turkall

2002

Human and Ecological Risk Assessment: An International Journal

View full text Add to dashboard Cite

A major goal of risk assessment is to protect the health of individuals who may be more sensitive than the general population. This study compared human pharmacokinetic and pharmacodynamic data in sensitive groups (i.e., children, the elderly, diseased states, and poor metabolizers) versus young, healthy adults for the antihistamines cetirizine, fexofenadine, loratadine, azelastine, ebastine, chlorpheniramine, and diphenhydramine.The default components (3.16 each for kinetic and dynamic aspects) of the intraspecies uncertainty factor were adjusted with compound specific data for the antihistamines. The majority (16 of 18) of the composite factors (kinetics × dynamics) for the sensitive groups were less than 10. Children had the lowest composite factors for antihistamines, ranging from 1.1 to 6.3. Application of kinetic and dynamic data for antihistamines to the Renwick/International Programme on Chemical Safety (IPCS) scheme can aid in characterizing the extent of variability in sensitive populations, thereby reducing the uncertainty associated with the risk assessment of sensitive populations.

show abstract

Section: Azelastinementioning

confidence: 99%